PDCD1 and lymphoma: Given 18.2%(8/44) patients in Arm B and 38.9%(7/18) patients in Arm D received>2 treatment lines before PD-1 inhibitor, subgroup analyses were also performed based on treatment line among patients with non-lymphoma group (Figure 3).